

Integrated Impact Assessment Report for Clinical Commissioning Policies			
Service Specification Reference Number	1661		
Service Specification Title	Adult Critical Care		
Lead Commissioner	Katharine Young	Clinical Leads	Jane Eddleston
Finance Lead	Peter Davies	Analytical Lead	

Integrated Impact Assessment - Index		
Section A – Activity	Section B - Service	Section C – Finance
A1 Current Patient Population & Demography / Growth	B1 Service Organisation	C1 Tariff
A2 Future Patient Population & Demography	B2 Geography & Access	C2 Average Cost per Patient
A3 Activity	B3 Implementation	C3 Overall Cost Impact of this Service Specification to NHS England
A4 Existing Patient Pathway	B4 Collaborative Commissioning	C4 Overall cost impact of this Service Specification to the NHS as a whole
A5 Comparator (next best alternative treatment) Patient Pathway		C5 Funding
A6 New Patient Pathway		C6 Financial Risks Associated with Implementing this Service Specification
A7 Treatment Setting		C7 Value for Money
A8 Coding		C8 Cost Profile
A9 Monitoring		

About this Impact Assessment: instructions for completion and explanatory notes

- Each section is divided into themes.
- Each theme sets out a number of questions.
- All questions are answered by selecting a drop down option or including free text.
- Free text boxes are provided to enable succinct relevant commentary to be added which explains the rationale for response or assumption. Please limit responses to 3 sentences of explanatory text.
- Data in this document is either drawn from one of the relevant Service Specification documents or a source for the information is provided.
- Where assumptions are included where data is not available, this is specified.

	Section A - Activity Impact
A1 Current Patient Population & Demography / Growth	h
A1.1 Prevalence of the disease/condition.	Adult Critical Care underpins all secondary and specialist adult services. Critical Care incorporates both intensive and high dependency care (ITU/HDU). Specifically this service specification is for adults who have a specialised commissioned pathway which incorporates the need for or availability to Adult Critical Care (level 2 and 3) as a component of their pathway of care.
A1.2 Number of patients currently eligible for the treatment according to the proposed Service Specification commissioning criteria.	The total number of critical care bed days billed to specialised commissioning is on average 41,000 per month. Source: Specialised Services Critical Care Activity Analysis 06/07/2018
A1.3 Age group for which the treatment is proposed according to the Service Specification commissioning criteria.	Adults defined as 18 years or older; but patients aged 16 to 18 years are also covered by this specification See 3.1 Service Specification Click here to enter text.
A1.4 Age distribution of the patient population eligible according to the proposed Service Specification commissioning criteria	Adults (see A1.3) Source: Service Specification section 3.1 Service Specification

A1.5 How is the population currently distributed geographically?	Evenly There is no known evidence of differences in geograpeople requiring critical care.	phical distril	bution in En	gland for
A2 Future Patient Population & Demography				
A2.1 Projected changes in the disease/condition epidemiology, such as incidence or prevalence (prior to applying the new Service Specification) in 2, 5, and 10 years?	Increasing Critical care activity has seen an average annual inc 2014. Source: Service Specification sec 3.2	rease of 3.8	% per year	since
A2.2 Are there likely to be changes in demography of the patient population and would this impact on activity/outcomes?	Yes With an ageing population the types of and number of specialised procedures undertaken are likely to increase. Source: Service Specification sec 3.3			
A2.3 Expected net increase or decrease in the number of patients who will be eligible for the service, according to the proposed service specification commissioning criteria, per year in years 2-5 and 10? The number of patients admitted to critical care for specialised services is recorded as payments to service providers are based on occupied bed days table below is an extract from the 2016-17 Reference Costs for Adult Critical care bed days and critical care periods (proximately patients). This covers both specialised and CCG commissioned care.		ed bed days Adult Critica ods (proxy fo	s. The I Care and	
	Type of Unit	No. of Critical Care Periods	No.ofBed Days	Average Length of Stay
	Burns and plastic surgery adult patients predominate	1,489	9,514	6.39
	Cardiac surgical adult patients predominate	51,984	178,077	3.43

Madical adult nationts/wassasified assasialtus	20.016	70.005	2.05
Medical adult patients (unspecified specialty)	20,016	78,995	3.95
Neurosciences adult patients predominate	15,531	76,843	4.95
Non-specific, general adult critical care patients			
predominate	216,843	967,637	4.46
Non-standard location using a ward area	4,180	17,946	4.29
Non-standard location using the operating department	3,119	7,733	2.48
Obstetric and gynaecology critical care patients			
predominate	4,419	10,049	2.27
Renal adult patients predominate	3,626	15,914	4.39
Spinal adult patients predominate	1,463	5,888	4.02
Surgical adult patients (unspecified specialty)	42,060	97,111	2.31
Thoracic surgical adult patients predominate	6,944	25,838	3.72
Grand Total	372,945	1,499,289	4.02

Source: 2016-17 National Reference Cost Collection

Are these numbers in line with ONS growth assumptions for the age specific population? If not please justify the growth assumptions made.

N/A

A3 Activity

A3.1 What is the purpose of new Service Specification?	Revise and update existing specification
A3.2 What is the annual activity associated with the existing pathway for the eligible population?	Patients requiring critical care will follow the current pathway (including eligibility criteria) See Service specification sec 2.1

A3.3 What is the estimated annual activity associated with the proposed Service Specification pathway for the eligible population?	No change – see A3.2 Source: Service Specification Working Group
A3.4 What is the estimated annual activity associated with the next best alternative comparator pathway for the eligible population? If the only alternative is the existing pathway, please state 'not applicable' and move to A4.	There is no other treatment option for patients who require level 2 and 3 critical care support Source: Service Specification Working Group
A4 Existing Patient Pathway	
A4.1 Existing pathway: Describe the relevant currently routinely commissioned: • Treatment or intervention • Patient pathway • Eligibility and/or uptake estimates.	No change in current pathway for treatment
A4.2. What are the current treatment access and stopping criteria?	Source: Service Specification, Service Specification Working Group
A4.3 What percentage of the total eligible population is expected to: a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	If not known, please specify a) 100% b) 0% c) 100% d) 100% e) 100% Source: Service Specification Working Group

A5 Comparator (next best alternative treatment) Patient Pathway

(NB: comparator/next best alternative does not refer to current pathway but to an alternative option)

A5.1 **Next best comparator**:

Is there another 'next best' alternative treatment which is a relevant comparator?

If yes, describe relevant

- Treatment or intervention
- Patient pathway
- · Actual or estimated eligibility and uptake

No

If yes, Click here to enter text.

Source: Service Specification Working Group

A5.2 What percentage of the total eligible population is estimated to:

- a) Be clinically assessed for treatment
- b) Be considered to meet an exclusion criteria following assessment
- c) Choose to initiate treatment
- d) Comply with treatment
- e) Complete treatment?

Not applicable

- a) 100%
- b) 0%
- c) 100%
- d) 100%
- e) 10%

Source: Service Specification working group

A6 New Patient Pathway

- A6.1 What percentage of the total eligible population is expected to:
 - a) Be clinically assessed for treatment
 - b) Be considered to meet an exclusion criteria following assessment
 - c) Choose to initiate treatment

If not known, please specify

- a) 100%
- b) 0%
- c) 100%
- d) 100%
- e) 100%

d) Comply with treatment e) Complete treatment?	Source: Service Specification Working Group	
A6.2 Specify the nature and duration of the proposed new treatment or intervention.	<u>Time limited</u> Source: Service Specification , Se	ervice Specification Working Group
A7 Treatment Setting		
A7.1 How is this treatment delivered to the patient?	Select all that apply:	
	Emergency/Urgent care attendan	ice 🗆
	Acute Trust: inpatient	
	Acute Trust: day patient	
	Acute Trust: outpatient	
	Mental Health provider: inpatient	
	Mental Health provider: outpatient	t 🗆
	Community setting	
	Homecare	
	Other	
	Please specify: Critical care unit	
A7.2 What is the current number of contracted providers	Critic	cal Care
for the eligible population by region?	NORTH	

	MIDLANDS & EAST		
	LONDON		
	SOUTH		
A7.3 Does this require a change of delivery setting or capacity requirements?	<u>No</u>		
capacity requirements:	Source: Service Specification Working Group		
A8 Coding			
A8.1 Specify the datasets used to record the new	Select all that apply:		
patient pathway activity.	Aggregate Contract Monitoring *		
*expected to be populated for all commissioned activity	Patient level contract monitoring		
	Patient level drugs dataset		
	Patient level devices dataset		
	Devices supply chain reconciliation dataset		
	Secondary Usage Service (SUS+)		
	Mental Health Services DataSet (MHSDS)		
	National Return**		
	Clinical Database**		
	Other**		

	**If National Return, Clinical database or other	selected, please specify:	
A8.2 Specify how the activity related to the new patient	Select all that apply:		
pathway will be identified.	OPCS v4.8		
	ICD10		
	Treatment function code		
	Main Speciality code		
	HRG		
	SNOMED		
	Clinical coding / terming methodology used by clinical profession		
A8.3 Identification Rules for Drugs: How are drug costs captured?	Not applicable		
A8.4 Identification Rules for Devices: How are device costs captured?	Not applicable		
A8.5 Identification Rules for Activity: How are activity costs captured?	Already correctly captured by an existing specialised service line (NCBPS code within the PSS Tool Adult critical care charges are linked to the associated inpatient spell and will therefore be recorded against numerous NCBPS codes.		

A9 Monitoring	
A9.1 Contracts Specify any new or revised data flow or data collection requirements, needed for inclusion in the NHS Standard Contract Information Schedule.	None Click here to enter text.
A9.2 Excluded Drugs and Devices (not covered by the Zero Cost Model) For treatments which are tariff excluded drugs or devices not covered by the Zero Cost Model, specify the pharmacy or device monitoring required, for example reporting or use of prior approval systems.	Select all that apply: Drugs or Device MDS Blueteq Other prior approval Please specify: Click here to enter text.
A9.3 Business intelligence Is there potential for duplicate reporting?	No If yes, please specify mitigation: Click here to enter text.
A9.4 Contract monitoring Is this part of routine contract monitoring?	Yes Reporting of activity via SUS with the associate activity spell
A9.5 Dashboard reporting Specify whether a dashboard exists for the proposed intervention?	Yes dashboard to be published alongside service specification Click here to enter text.

<u>No</u>
Section B - Service Impact
Source: Service Specification
<u>No</u>
Source: Service Specification Working Group
No
Select all that apply:
GP
Secondary care

	Towling Core
	Tertiary care
	Other 🗵
	Emergency departments
B2.2 What impact will the new Service Specification have on the sources of referral?	No impact .
B2.3 Is the new Service Specification likely to improve	No impact
equity of access?	Please specify:
	Source: Equalities Impact Assessment
B2.4 Is the new Service Specification likely to improve	Increase
equality of access and/or outcomes?	Please specify:
	Will improve outcomes for patients due to increased compliance with best practice standards
B3 Implementation	
B3.1 Will commissioning or provider action be required	No action required
before implementation of the specification can occur?	Please specify:
	The specification adds further clarification to the current published specification and updates this
B3.2 Time to implementation:	<u>No - go to B3.4</u>

Is a lead-in time required prior to implementation?	If yes, specify the likely time to implementation:
B3.3 Time to implementation: If lead-in time is required prior to implementation, will an interim plan for implementation be required?	No - go to B3.4 : Click here to enter text.
B3.4 Is a change in provider physical infrastructure required?	<u>No</u>
B3.5 Is a change in provider staffing required?	No See above
B3.6 Are there new clinical dependency and/or adjacency requirements that would need to be in place?	No Please specify:
B3.7 Are there changes in the support services that need to be in place?	No Please specify:
B3.8 Is there a change in provider and/or inter-provider governance required? (e.g. ODN arrangements / prime contractor)	No Please specify:
B3.9 Is there likely to be either an increase or decrease in the number of commissioned providers? If yes,	Increase Please complete table: Not applicable

specify the current and estimated number of providers required in each region	Region	Current no. of providers	Future State expected range	Provisional or confirmed	
	North	8	8	С	
	Midlands & East	5	5	<u>P</u>	
	London	6	6	<u>C</u>	
	South	5	5	<u>C</u>	
	Total	24	24	<u>C</u>	
	Please specify Not applicable				
B3.10 Specify how revised provision will be secured by	Select all that apply:				
NHS England as the responsible commissioner.	Publication a Specification	and notification of	new Service	\boxtimes	
	Market interv	vention required			
		selection process	s to secure increase or on		
	Price-based selection process to maximise cost effectiveness				
	Any qualified provider				
	National Commercial Agreements e.g. drugs, devices				
	Procurement				
	Other				
	Please specif	·y:			

	Click here to enter text.		
B4 Place-based Commissioning			
B4.1 Is this service currently subject to, or planned for, place-based commissioning arrangements? (e.g. future CCG lead, devolved commissioning arrangements, STPs)	No Please specify: Click here to enter text.		
	Section C	- Finance Impact	
C1 Tariff/Pricing			
C1.1 How is the service contracted and/or charged?	Select all	that apply:	
Only specify for the relevant section of the patient pathway	Drugs	Not separately charged – part of local or national tariffs	
		Excluded from tariff – pass through	
		Excluded from tariff - other	
		Not separately charged – part of local or national tariffs	
	Devices	Excluded from tariff (excluding ZCM) – pass through	
		Excluded from tariff (excluding ZCM) - other	
		Via Zero Cost Model	
	Activity	Paid entirely by National Tariffs	
		Paid entirely by Local Tariffs	
		Partially paid by National Tariffs	

		Partially paid by Local Tariffs	\boxtimes
		Part/fully paid under a Block arrangement	\boxtimes
		Part/fully paid under Pass-Through arrangements	
		Part/fully paid under Other arrangements	
C1.2 Drug Costs Where not included in national or local tariffs, list each drug or combination, dosage, quantity, list price including VAT if applicable and any other key information e.g. Chemotherapy Regime.	Not applica	ble	
NB discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.			
C1.3 Device Costs Where not included in national or local tariff, list each element of the excluded device, quantity, list or expected price including VAT if applicable and any other key information. NB: Discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.	Not applica	ble	
C1.4 Activity Costs covered by National Tariffs List all the HRG codes, HRG descriptions, national tariffs (excluding MFF), volume and other key costs (e.g. specialist top up %)	Not applica	ble	

C1.5 Activity Costs covered by Local Tariff List all the HRGs (if applicable), HRG or local description, estimated average tariff, volume and any other key costs. Also indicate whether the Local Tariff(s) is/are newly proposed or established and if newly proposed how is has been derived, validated and tested.	There is a nationally mandated currency for adult critical care as follows: XC01Z Adult Critical Care, 6 or more Organs Supported XC02Z Adult Critical Care, 5 Organs Supported XC03Z Adult Critical Care, 4 Organs Supported XC04Z Adult Critical Care, 3 Organs Supported XC05Z Adult Critical Care, 2 Organs Supported XC06Z Adult Critical Care, 1 Organ Supported XC07Z Adult Critical Care, 0 Organs Supported The average cost per bed day as per 2016/17 Reference Costs is £1,296
C1.6 Other Activity Costs not covered by National or Local Tariff Include descriptions and estimates of all key costs.	Not applicable
C1.7 Are there any prior approval mechanisms required either during implementation or permanently?	No Please specify:
C2 Average Cost per Patient	
C2.1 What is the estimated cost per patient to NHS England, in years 1-5, including follow-up where required? Are there any changes expected in year 6-10 which would impact the model?	The average cost per critical care period in 2016/17 was £5,210. No

C3.1 Specify the budget impact of the proposal on NHS England in relation to the relevant pathway.	<u>Cost neutral</u>
	A separate analysis of the service specification standards has been undertaken to assess any potential financial impact and it is not anticipated that there will be any direct impact on local prices.
C4 Overall cost impact of this Service Specification to	o the NHS as a whole
C4.1 Specify the budget impact of the proposal on other	Budget impact for CCGs:
parts of the NHS.	Cost neutral
	Budget impact for providers:
	No impact on providers
	Please specify:
	It is not anticipated that there will be an impact on providers as most providers should already be meeting the standards set out in the service specification.
C4.2 Taking into account responses to C3.1 and C4.1	Cost neutral
specify the budget impact to the NHS as a whole.	Please specify: Cost neutral as updating current service specification.
C4.3 Where the budget impact is unknown set out the reasons why this cannot be measured	Not applicable
C4.4 Are there likely to be any costs or savings for non-	No
NHS commissioners and/or public sector funders?	Please specify:

C5 Funding			
C5.1 Where a cost pressure is indicated, state known source of funds for investment, where identified, e.g. decommissioning less clinically or cost-effective services.	N/A		
C6 Financial Risks Associated with Implementing this Service Specification			
C6.1 What are the material financial risks to implementing this Service Specification?	Not applicable		
C6.2 How can these risks be mitigated?	Not applicable		
C6.3 What scenarios (differential assumptions) have been explicitly tested to generate best case, worst case and most likely total cost scenarios?	Not applicable		
C6.4 What scenario has been approved and why?	Not applicable		
C7 Value for Money			
C7.1 What published evidence is available that the treatment is cost effective as evidenced in the evidence	Published evidence indicates the treatment has the potential to be cost-effective Please specify:		

review?	NICE- TAs listed within the specification	
C7.2 Has other data been identified through the service	Select all that apply:	
specification development relevant to the assessment of value for money?		
	Available pricing data suggests the treatment is equivalent cost compared to current/comparator treatment	
	Available pricing data suggests the treatment is lower cost compared to current/comparator treatment	
	Available clinical practice data suggests the new treatment has the potential to improve value for money	
	Other data has been identified	
	No data has been identified	
	The data supports a high level of certainty about the impact on value	
	The data does not support a high level of certainty about the impact on value	
	Please specify:	
C8 Cost Profile		
C8.1 Are there non-recurrent capital or revenue costs associated with this Service Specification?	No If yes, specify type and range:	

C8.2 If yes, confirm the source of funds to meet these	
costs.	

